双示踪剂PET/CT在原发性肺类癌诊断与预后中的作用
该回顾性多中心研究纳入61例原发性肺类癌患者,联合[18F]FDG与[68Ga]-DOTA-peptides PET/CT进行双示踪评分(1-4分)并计算SUVr;典型类癌SUVr中位数为6.4,非典型类癌为0.4(p=0.011),SUVr预测最终诊断的最佳值为1.05(AUC 0.889),双示踪评分及AC诊断与PFS显著相关。
要点
- 典型类癌多表现为DOTA阳性/FDG阴性,非典型类癌多为FDG阳性
- SUVr(DOTA/FDG的SUVmax比值)有助于鉴别TC与AC,最佳阈值1.05
- 双示踪评分及AC诊断与PFS相关,仅AC诊断与OS相关
核心结论
- 双示踪PET/CT表现可用于预测肺类癌性质并辅助选择最合适的管理策略。
- PET/CT表现对预测PFS具有预后作用。
研究设计与样本
- 回顾性多中心研究,来自三个中心,共纳入61例患者。
- 基于双示踪组合将PET扫描分为评分1(FDG与DOTA均阴性)、2(DOTA阳性、FDG阴性)、3(DOTA阴性、FDG阳性)、4(两者均阳性)。
- 计算每位患者[68Ga]-DOTA-PET与[18F]FDG-PET的SUVmax比值(SUVr)。
关键影像表现/征象
- 22例TC(57%)[68Ga]-DOTA-peptides PET阳性。
- 21/26(81%)非典型类癌(AC)[18F]FDG-PET/CT阳性。
- 双示踪分析中评分1、2、3、4在全体人群分别为13%、20%、43%、24%。
- TC中评分1、2、3、4分别为17%、26%、20%、37%;AC中分别为8%、11%、73%、8%。
诊断标准与关键数值
- SUVr预测最终诊断的最佳值为1.05,AUC为0.889。
- TC的SUVr中位数显著高于AC(6.4 vs. 0.4,p=0.011)。
临床应用与阅片要点
- 阅片时可结合FDG与DOTA双示踪结果及评分判断TC与AC倾向。
- 计算DOTA/FDG的SUVmax比值(SUVr)辅助鉴别,注意阈值1.05来自本组数据。
- 报告中可提示双示踪评分及AC诊断与PFS相关,供临床随访参考。
局限性
- 回顾性研究设计。
- 样本量较小(61例),来自三个中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: In the present retrospective multicentric study, we combined [68Ga]-DOTA-peptides and [18F]FDG-PET/CT findings aiming to investigate their capability to differentiate typical (TC) and atypical pulmonary carcinoids (AC) and their prognostic role.
METHODS: From three centers, 61 patients were retrospectively included. Based on a dual tracer combination we classified PET scans as score 1, [18F]FDG- and [68Ga]-DOTA-peptides negative; score 2, [68Ga]-DOTA-peptides positive and [18F]FDG-negative; score 3, [68Ga]-DOTA-peptides negative and [18F]FDG-positive; score 4, both tracers positive. Moreover, for each patient, the ratios of SUVmax on [68Ga]-DOTA-PET to that on [18F]FDG-PET were calculated (SUVr).
RESULTS: Thirty-five patients had a final diagnosis of TC. Twenty-two TC (57%) had positive [68Ga]-DOTA-peptides PET; instead, 21/26 (81%) AC had positive [18F]FDG-PET/CT. On dual-tracer analysis, scores 1, 2, 3 and 4 were 13%, 20%, 43% and 24% for all populations; 17%, 26%, 20% and 37% for TC; 8%, 11%, 73% and 8% for AC. Median SUVr was significantly higher in TC than AC (6.4 vs. 0.4, p = 0.011). The best value of SUVr to predict the final diagnosis was 1.05 (AUC 0.889). Relapse or progression of disease happened in 17 patients (11 affected by AC) and death in 10 cases (7 AC). AC diagnosis, positive [18F]FDG-PET, negative DOTA-PET and dual tracer score were significantly correlated with PFS (p = 0.013, p = 0.033, p = 0.029 and p = 0.019), while only AC diagnosis with OS (p = 0.022).
CONCLUSION: PET/CT findings had also a prognostic role in predicting PFS. Dual-tracer PET behavior may be used to predict the nature of pulmonary carcinoids and select the most appropriate management.
KEY POINTS: • Combination of [18F]FDG and [68Ga]-DOTA-peptides PET/CT results may help to differentiate between atypical and typical lung carcinoids. • The SUVmax ratio between [18F]FDG and [68Ga]-DOTA-peptides PET may help to differentiate between atypical and typical lung carcinoids. • Histotype and PET/CT features have a prognostic impact on PFS.
引用
- Albano, Dondi, Bauckneht, et al. The diagnostic and prognostic role of combined [18F]FDG and [68Ga]-DOTA-peptides PET/CT in primary pulmonary carcinoids: a multicentric experience. Eur Radiol. 2022. PMID: 36482218. doi:10.1007/s00330-022-09326-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。